Some Apple employees have become disillusioned with the group's culture, where some have thrived while others feel sidelined.Technologyread more
Biden has shown staying power at the top of a jammed Democratic field even as polling numbers for Sanders, Warren and Harris wax and wane.2020 Electionsread more
President Donald Trump believes he has quite the bargaining chip with the European Union.Marketsread more
President Donald Trump renewed calls Tuesday of re-admitting Russia to the G7 ahead of the group's summit in Biarritz, France this weekend.Politicsread more
The FDIC on Tuesday votes to approve a five-agency revision of the post-crisis regulation known as the Volcker Rule.Financeread more
The yield curve is the only economic indicator pointing to a recession, according to Credit Suisse.Marketsread more
Amid fears of a recession, Domino's Pizza CEO Ritch Allison said Tuesday that the U.S. consumer is still strong.Restaurantsread more
Stocks slipped on Tuesday as investors digested a sharp rebound from a strong sell-off last week.US Marketsread more
It was a good day for Home Depot shareholders as the home improvement retailer's stock rose more than 4% on stronger-than-expected earnings.Marketsread more
Makan Delrahim, assistant attorney general for the antitrust division, said several state attorneys general have spoken to the Justice Department about starting their own...Technologyread more
With the official launch of the Apple Card, Goldman Sachs has embarked on a multi-decade journey to becoming a leader in consumer banking, CEO David Solomon says.Financeread more
"Add a ZIP code to the scissors and direct it to specific regions of your human genome to make edits, very similar to Microsoft Word where you are fixing a word that may have been misspelled," Nessan Bermingham said in an interview with CNBC's "Closing Bell " on Thursday.
Right now, any genetic disease is on the table. The technology can repair a mutation or modification within the DNA or insert a fragment of DNA to allow the company to generate a therapeutic protein for a specific disease, he said.
"We are now actually starting to better understand application and the breadth of the application of the technology today."
Intellia Therapeutics went public in May and spiked 20 percent on its first day on the market.
While the trend has been for companies to stay private, Bermingham said it was important to access the capital.
"As we think about building the pipeline and the platform, having access to a lot of capital allows us to actually build it rapidly and move it quickly into the clinic," he explained.
In fact, the discovery of the technology occurred in 2012 and the first human clinical trials are already planned for 2017 and 2018.
The money needed for that can't be raised in the private market, he said.
"We know in a model system this does work. Now it's translating that into human therapeutic application," he said.